MSB11456

DRUG2 trials

Sponsors

Fresenius Kabi SwissBioSim GmbH

Conditions

HealthyRheumatoid Arthritis

Phase 1

Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

CompletedNCT03282851

Fresenius Kabi SwissBioSim GmbHHealthy

Start: 2017-11-27End: 2019-10-01Updated: 2020-02-12

Phase 3

MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis

CompletedNCT04512001

Fresenius Kabi SwissBioSim GmbHRheumatoid Arthritis

Start: 2020-08-03End: 2022-06-06Updated: 2023-06-27

Related Papers

Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study

RMD Open2024-02-016 citations